Lastly, it should be pointed out that the CANMAT guidelines determined the evidence for non-IV formulations of racemic ketamine to be limited to Degree 3 or 4. The AJP A chemical by-product of ketamine called esketamine was approved because of the FDA in 2019 to be used in refractory depression. https://francisb445cth3.blogchaat.com/profile